MiNK

MiNK is a clinical-stage biotechnology company developing allogeneic, off-the-shelf invariant natural killer T cell therapies. Its pipeline includes native and engineered iNKT programs for oncology, critical illness, transplantation, and other immune-mediated conditions, supported by proprietary manufacturing capabilities and licensed Agenus technology.

Relationship details are part of the Pro plan.